The global endocrine testing market size was valued at USD 7.04 billion in 2016 and is expected to witness a CAGR of 8.0% over the forecast period. Growing incidences of endocrine disorders such as hyperthyroidism and adrenal insufficiency are predicted to boost the demand for endocrine testing.
The growing diabetic, geriatric, and obese population worldwide is expected to promote market growth. Furthermore, growing healthcare awareness among individuals coupled with increasing government support is expected to increase the diagnosis at an early, thereby contributing to the growth of the endocrine testing market.
The growing prevalence of lifestyle diseases is also expected to contribute to the demand for the endocrine test, thereby contributing to the market growth. Rising cases for diseases such as hypothyroidism and hyperthyroidism is also expected to propel the demand for advanced endocrine testing technologies.
Advancement in technologies such as introduction of easy-to-operate test kits facilitated the penetration of home-based diagnosis, which is user-friendly and cost-effective. Moreover, the target of this market is the geriatric population owing to its increased susceptibility to chronic diseases and the high risk of developing complications at an older age, which makes continuous monitoring essential in these elderly patients.
Owing to increasing health awareness around the world, there has been advancement in home health care along with easy operating home diagnostic kits which are cost-effective and designed with precision. Many new mass spectrometric technologies have been introduced which deliver accurate results in less time and they are highly sensitive.
Mass Spectrometry is now coupled with liquid chromatography for more precision. Telehealth services have also been introduced by some commercial laboratories and stand-alone clinics. Fully automated systems have been designed for faster diagnosis and increased sample size testing.
The rising number of healthcare settings, especially in developing regions is fostering the growth of the endocrine testing market. For instance, in 2014, Saudi Arabia's government allocated USD 28 billion in health and development sectors. With the help of this grant, 17 new hospitals, and the expansion of 137 hospitals and primary health centers are anticipated. Similarly, in Qatar, the number of hospital beds is expected to rise from 4,980 in 2013 to 5,725 in 2018. These expansions are expected to create avenues for the therapeutic market.
Based on test type, the market is segmented into Estradiol (E2), Human Chorionic Gonadotropin (hCG), Follicle Stimulating (FSH), Dehydroepiandrosterone sulfate (DHEAS), Progesterone, Luteinizing Hormone (LH), testosterone, thyroid prolactin, Thyroid Stimulating Hormone (TSH), cortisol, insulin, and other tests such as gastrin, thymosin, and secretin tests.
Thyroid-stimulating hormone (TSH) test accounted for a lucrative share in 2016, This can be attributed to the increasing incidences of TSH-related disorders and the growing awareness regarding the correlation between variations in the thyroid hormones levels and cardiovascular disorders.
The insulin test is anticipated to witness the fastest growth over the forecast period. The substantial rise in the diabetic population and the growing awareness about diagnosis are anticipated to contribute towards the demand for insulin tests over the forecast period.
Key technology segments include tandem mass spectrometry, immunoassay, monoclonal & polyclonal antibody technologies, sensors, clinical chemistry technologies, and others such as Liquid Chromatography with Mass Spectrometry (LC-MS).
The tandem mass spectrometry is expected to dominate the market during the forecast period. This can be attributed to growing use of tandem mass spectrometry in combination with liquid chromatography which helps in overcoming the challenges associated with traditional techniques used for endocrine testing.
Sensor Technology is expected to show the fastest growth among all the segments owing to growing use of biosensors in glucose monitoring for diabetes which is used on routine basis by the individuals to monitor their blood sugar level in undiluted blood samples.
The market based on end-use is segmented into hospitals, commercial laboratories, ambulatory care centers, and other healthcare settings. The hospital segment accounted for the largest share in 2016 and is expected to dominate the market during the forecast period.
The commercial laboratory segment is expected to witness the fastest growth owing to availability of advanced infrastructure coupled with skilled personnel.
Geographically, the endocrine testing market is segmented into North America, Europe, Asia Pacific, Latin America, and MEA. The presence of well-developed primary, secondary, tertiary care hospitals supported the growth in the North American region. Moreover, a well-developed reimbursement network, favorable government funding, and increasing health awareness facilitated the usage of advanced techniques for endocrine testing.
Asia-Pacific endocrine testing market is expected to witness a lucrative CAGR of 9.1% over the forecast period. Key factors attributed to market growth include growing R&D expenditure by the government and private agencies in order to improve diagnostic and therapeutic areas in the region. Economic development in countries such as India, China, and Japan coupled with favorable government initiatives pertaining to the development of healthcare infrastructure and reimbursement policies are further expected to fuel market growth.
The major share in endocrine testing market share is held by companies such as Abbott Laboratories, AB Sciex, Agilent Technologies, Biomedical Technologies, bioMerieux SA, Bio Rad Laboratories, DiaSorin, Hoffmann-La Roche Ltd., LabCorp, and Quest Diagnostics.
The players are actively involved in launching technologically advanced products and initiate collaborative developments to sustain themselves in the competition. For instance, LabCorp offers all-embracing solutions on clinical trials pertaining to diabetes and all other hormonal diseases. In addition, the company also provides liquid chromatography in combination with mass spectrometry to yield specific results even with minimal amounts of the hormonal sample.
Report Attribute |
Details |
Market size value in 2020 |
USD 9.5 billion |
Revenue forecast in 2024 |
USD 13.02 billion |
Growth Rate |
CAGR of 8.0% from 2017 to 2024 |
Base year for estimation |
2016 |
Historical data |
2013 - 2015 |
Forecast period |
2017 - 2024 |
Quantitative units |
Revenue in USD million and CAGR from 2017 to 2024 |
Report coverage |
Revenue forecast, company share, competitive landscape, growth factors and trends |
Segments covered |
Test type, technology, end-use, region |
Regional scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
Country scope |
U.S.; Canada; U.K.; Germany; Japan; China; Brazil; Argentina; South Africa |
Key companies profiled |
Abbott Laboratories; AB Sciex; Agilent Technologies; Biomedical Technologies; bioMerieux SA, Bio Rad Laboratories; DiaSorin; Hoffmann-La Roche; LabCorp; Quest Diagnostics |
Customization scope |
Free report customization (equivalent up to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope. |
Pricing and purchase options |
Avail customized purchase options to meet your exact research needs. Explore purchase options |
This report forecasts revenue growth at global, regional, & country levels as well as provides an analysis on the latest trends and opportunities in each of the sub-segments from 2013 to 2024. For the purpose of this study, Grand View Research has segmented the global endocrine testing market report on the basis of test type, technology, end use, and region
Test Type Outlook (Revenue, USD Million, 2013 - 2024)
Estradiol
FSH
hCG
LH
DHEAS
Progesterone
Testosterone
TSH
Prolactin
Cortisol
Insulin
Others
Technology Outlook (Revenue, USD Million, 2013 - 2024)
Tandem Mass Spectrometry
Immunoassay
Monoclonal & Polyclonal antibody technologies
Sensor technology
Clinical chemistry
Others
End-use Outlook (Revenue, USD Million, 2013 - 2024)
Hospital
Commercial Laboratory
Ambulatory Care Centers
Others
Regional Outlook (Revenue, USD Million, 2013 - 2024)
North America
The U.S.
Canada
Europe
The U.K.
Germany
Asia Pacific
Japan
China
Latin America
Brazil
Mexico
MEA
South Africa
b. The global endocrine testing market size was estimated at USD 8.8 billion in 2019 and is expected to reach USD 9.5 billion in 2020.
b. The global endocrine testing market is expected to grow at a compound annual growth rate of 7.4% from 2020 to 2027 to reach USD 16.8 billion by 2027.
b. North America dominated the endocrine testing market with a share of 39.3% in 2019. This is attributable to the presence of well-established healthcare infrastructure and favorable healthcare reimbursement scenarios in the North American region.
b. Some key players operating in the endocrine testing market include Abbott Laboratories; AB Sciex; Agilent Technologies; Biomedical Technologies; bioMerieux SA, Bio Rad Laboratories; DiaSorin; Hoffmann-La Roche; LabCorp; and Quest Diagnostics.
b. Key factors that are driving the endocrine testing market growth include growing incidences of endocrine disorders such as hyperthyroidism and adrenal insufficiency.
This report has a service guarantee. We stand by our report quality.
We are in compliance with GDPR & CCPR norms. All interactions are confidential.
Design an exclusive study to serve your research needs.
Get your queries resolved from an industry expert.
"The quality of research they have done for us has been excellent..."
The most common concern for the governments of all Covid-19 hit nations is the excruciating need to screen for and test large numbers of patients for possible Sars-Cov-2 infection. As a result, most of them are facing major shortages in the supply for diagnostic kits to test for the virus. Diagnostics virology entities are under immense pressure to provide reliable testing kits, and there is a surge in demand for in-vitro or point-of-care testing capacities by labs across a large number of countries. The report will account for Covid19 as a key market contributor.